First-in-Human trial launches for new weapon against tough GI cancers
NCT ID NCT06663319
Summary
This is the first study in people of an experimental drug called JNJ-89402638 for advanced colorectal and stomach cancers that have spread and stopped responding to standard treatments. The main goals are to find a safe dose and see how the body handles the drug, both alone and when combined with other cancer therapies. It will enroll about 220 adults whose cancer has progressed after prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Community Health Network
RECRUITINGIndianapolis, Indiana, 46256, United States
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
-
Hosp Univ Fund Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
-
Hosp Univ Hm Sanchinarro
RECRUITINGMadrid, 28050, Spain
-
Hosp Univ Vall D Hebron
RECRUITINGBarcelona, 08035, Spain
-
Hosp. Univ. 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Start Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
Swedish Cancer Institute
RECRUITINGSeattle, Washington, 98104, United States
-
University of Colorado Denver Anschultz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.